22 6月 2020 by admin in UncategorizedComments TEMPEST THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED WITH THE COMBINATION OF TPST-1120 PLUS NIVOLUMAB IN A PHASE 1 STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS
